Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 1 of 14 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
|
|
- Judith Caldwell
- 5 years ago
- Views:
Transcription
1 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 1 of 14 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA MYLAN LABORATORIES, INC., et al., Plaintiffs, v. Civil Action No (RMU MICHAEL O. LEAVITT, Secretary, Health and Human Services, et. al., Defendants, and TEVA PHARMACEUTICALS USA, INC., APOTEX INC., and MUTUAL PHARMACEUTICAL CO., INC., Intervenors. GOVERNMENT DEFENDANTS OPPOSITION TO MYLAN S APPLICATION FOR TEMPORARY RESTRAINING ORDER FILED JUNE 26, 2007 INTRODUCTION In plaintiffs (hereinafter Mylan motion for a temporary restraining order filed yesterday, Mylan s principal argument is based on an issue it raised in its first request for emergency relief, which it filed in this Court in April That issue was rejected by this Court, Mylan Labs., Inc. v. Leavitt, 484 F. Supp. 2d 109 (D.D.C. 2007, and is now on appeal. Under the law of this Circuit, this Court has no jurisdiction to revisit that issue at this time. For this reason, Mylan s application should be denied. Even if the Court were to examine this issue, however, it has no merit and should be rejected.
2 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 2 of 14 What precipitated Mylan s latest attempt to restrict competition for amlodipine besylate tablets ( amlodipine is Pfizer s request to remove the only remaining patent for this product, United States Patent No. 4,879,303 ( 303 patent, from the Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book. On June 22, 2007, FDA removed the patent from the Orange Book and sent a letter to the drug manufacturers who had submitted ANDAs for amlodipine (including Mylan, notifying them of this event and explaining why FDA took this action. (FDA s June 22, 2007, letter is attached to Mylan s motion as Exhibit A. FDA explained that Pfizer requested the removal of the patent because it no longer met the criteria for listing in the Orange Book, and FDA generally defers to the NDA holder s judgment about whether a patent should be listed. Although there are exceptions to that practice, FDA examined those exceptions and determined they did not apply. Thus, there was no barrier to delisting the patent. See Mylan Ex. A. As the Court is aware, it was this patent to which Pfizer s six-month pediatric exclusivity for amlodipine attached and which precluded FDA approval of all generic products other than those of Mylan and Apotex. The removal of this patent now opens the way for FDA approval of other generics. In the prior round of litigation on this matter, Mylan relied principally on Pfizer s pediatric exclusivity to argue that other generics should not be approved. With the delisting of the patent, however, Pfizer has waived its claim to any remaining pediatric exclusivity. Recognizing this, Mylan has apparently abandoned its reliance on Pfizer s pediatric exclusivity to shield itself from competition. Mylan is now relying on an alleged 180 days of exclusivity to preclude FDA approval of other generics and the delisting of the 303 patent. Although not in the context of delisting, Mylan presented its 180-day marketing exclusivity argument to this Court in its first request for emergency relief and the Court squarely -2-
3 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 3 of 14 rejected it on the ground that the 303 patent had expired. Pfizer s request to delist the patent does not change this Court s prior analysis (and rejection of Mylan s claim to 180 days of marketing exclusivity. Mylan did not have 180 days of exclusivity then because the patent was expired, and the delisting of the patent did not change that. This Court rejected Mylan s argument because the patent had expired, not because it was or was not listed. Thus, Pfizer s delisting of the patent did not change the analysis of the 180-day issue (although delisting serves to moot the pediatric exclusivity issue. Hence, whether or not the 303 patent were delisted, Mylan would not have 180 days of exclusivity. Rather, Mylan is seeking to use FDA s decision to delist the patent to resurrect the 180-day issue. Because Mylan has already lost this issue in this Court and has appealed it, it cannot reargue the issue now and, in fact, this Court lacks jurisdiction to hear it. Even in the absence of the jurisdictional defect, however, Mylan has no claim to exclusivity because the patent has expired. Pfizer s delisting of the patent does not change this result; in fact, FDA s decision to remove the patent from the Orange Book involved a clearly appropriate application of established law. For all of these reasons, Mylan has little likelihood of success on the merits. Mylan cannot establish the other requirements for emergency relief. Now that Mylan shares the generic amlodipine market with a Pfizer affiliate as well as Apotex, its claims of irreparable harm from the addition of each new competitor can only be diminishing. Further, any harm to Mylan is offset by the benefit to these other manufacturers. Finally, additional competition brought on by more manufacturers will benefit the public, and the public will benefit from the faithful and proper application of the law. -3-
4 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 4 of 14 BACKGROUND Because this Court has already issued two decisions on the merits in this case over the last few months, the government will not describe at length the legal and factual background to this case. To briefly summarize the issues relevant to the instant motion, Mylan has claimed in this litigation that FDA approvals of its competitors ANDAs are blocked by Pfizer s pediatric exclusivity, an award of six months of exclusivity beyond the expiration date of a patent for new drug manufacturers who complete pediatric studies pursuant to a request from FDA, and by Mylan s 180-day marketing exclusivity, an incentive for the first applicant for the generic version of a new drug to challenge the innovator s patent for that drug. Pfizer s decision to delist the patent is in essence a waiver of any remaining claim to pediatric exclusivity that it still had because a listed patent is a threshold requirement for pediatric exclusivity. Mylan Ex. A at 2. Accordingly, with the delisting of the patent, all other ANDA applicants may seek final approval from FDA now, rather than waiting for the expiration of pediatric exclusivity on September 25, See id. I. Pediatric Exclusivity By the terms of the relevant statutory provisions, pediatric exclusivity applies only to the extent there is a patent listed in the Orange Book to which unapproved ANDAs have submitted patent certifications. 21 U.S.C. 355a(c. Patents are required to be listed in FDA s Orange Book if they claim the approved drug substance, approved drug product, or an approved method of use. 21 U.S.C. 355(b(1; 21 C.F.R If certain claims of a patent are declared invalid, but one or more of the remaining patent claims claims the approved drug substance, -4-
5 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 5 of 14 approved drug product, or approved method of use, the patent can remain properly listed until the expiration of pediatric exclusivity. The Federal Circuit determined that three claims in the 303 patent that Pfizer asserted that Apotex infringed were invalid as obvious, Pfizer Inc. v. Apotex, Inc., No , 2007 U.S. App. LEXIS 6623 (Fed. Cir. March 22, 2007, mandate issued, (Fed. Cir. May 21, However, that litigation did not resolve whether the 303 patent had continued vitality with respect to other ANDAs. The 303 patent could remain in the Orange Book if the remaining claims continued to satisfy the requirements for listing. Although some ANDA applicants asserted that the claims did not meet those requirements, FDA concluded that it lacked the information and expertise to resolve that issue, and therefore could not declare that the other ANDAs were no longer barred by pediatric exclusivity or that the patent should be delisted. See FDA Letter Decision of April 18, 2007, at 10 (submitted to the Court on April 18, 2007 (hereinafter FDA Decision. However, FDA did not foreclose the possibility that other information may come to light that would allow FDA to conclude that the patent is invalid: FDA stated that in the absence of further judicial or other action clarifying the status of the patent, FDA will assume the 303 patent remains validly listed. Id. at 10 (emphasis added. Now Pfizer has resolved that question by delisting the patent. By letter dated June 14, 2007, Pfizer informed FDA that the 303 patent no longer meets the requirements for listing. Mylan Ex. A at 1. FDA delisted the patent on June 22, Id. As FDA explained in its letter to the ANDA applicants, FDA s role in patent listing is ministerial, and FDA defers to the NDA holder s judgment regarding the listing of patents. Id. Pfizer has waived any remaining claim it -5-
6 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 6 of 14 had to pediatric exclusivity, and ANDA applicants lack standing to challenge that waiver. Id. at 2 n.3. Mylan does not raise any arguments about pediatric exclusivity in its current motion. 1 II. 180-Day Marketing Exclusivity With respect to 180-day exclusivity, this Court correctly held as follows: The FDA ruled that Mylan s 180-day market exclusivity does not extend beyond patent expiration. FDA Decision at 10. Mylan challenges this ruling, arguing that once triggered, the 180-day market exclusivity period remains regardless of the status of the patent. Mylan s Mot. at 12. The genesis of the 180-day exclusivity period is that the statute prevents the FDA from granting paragraph IV certification ANDAs for 180 days. 21 U.S.C. 355(j(5(B(iv. Mylan contends that nothing in the text or legislative history of the Hatch-Waxman Act indicates that generic exclusivity is forfeited upon patent expiration. Mylan s Mot. at 12. This is not correct. Under Hatch-Waxman, paragraph IV certifications are no longer valid upon patent expiration. 21 U.S.C. 355(j(2(A(vii(II, (IV. Under applicable regulations, ANDA applicants must change their paragraph IV certifications to paragraph II certifications when the certification becomes invalid. 21 C.F.R (a(12(viii(C. When a patent has expired, those applications with paragraph II certifications (including those converted from paragraph IV certifications are eligible for immediate drug approval. 21 U.S.C. 355(j(5(B(I. In this case, when Pfizer s Norvasc patent expired on March 25, 2007, all paragraph IV certifications converted to paragraph II certifications and became eligible for approval. Id. The statutory provision cited by Mylan which entitles it to market exclusivity, by its terms, applies only to paragraph IV certifications, which cease to exist upon patent expiration. 21 U.S.C. 355 (j(5(b(iv. Accordingly, the FDA s conclusion that Mylan's 180-exclusivity does not survive patent expiration constitutes a reasonable interpretation of the statute. And for this reason, Mylan fails to convince the court that it has a substantial likelihood of success on this claim. 1 Because the patent is delisted, Mylan s challenge regarding FDA s pediatric exclusivity determination is now moot. Although Mylan does not explicitly concede that point, Mylan states [n]ow that the FDA has delisted the Pfizer patent, Mylan s claim to 180-day exclusivity has moved to the forefront. Mylan Br. at 2. Because the pediatric exclusivity issue is currently before the D.C. Circuit, this Court need not resolve the mootness issue. -6-
7 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 7 of 14 Mylan Labs., Inc. v. Leavitt, 484 F. Supp. 2d at (citations omitted. Mylan appealed the entirety of this Court s decision, and it also raised this issue in its motion for injunction pending appeal filed with the Court of Appeals. Mylan is now attempting to bring the 180-day exclusivity issue back to the forefront. However, the patent s expiration should be the end of the matter. As FDA explained in its June 22 letter, an exception to delisting is set forth in 21 C.F.R (a(12(viii, which provides: A patent that is the subject of a lawsuit under (c 2 shall not be removed from the list until FDA determines either that no delay in effective dates of approval is required under that section as a result of the lawsuit, that the patent has expired, or that any such period of delay in effective dates of approval is ended. Thus, under section (a(12(viii, FDA can refuse to remove a patent from the Orange Book when an otherwise valid 180-day exclusivity claim would be prematurely extinguished by the delisting of the patent. However, under the terms of the regulation, the 180-day exclusivity claim ceases to be a barrier to delisting after the patent has expired or the exclusivity period no longer operates to delay the approval of other ANDAs. 21 C.F.R (a(12(viii. Here, because Mylan s exclusivity expired with the patent on March 25, 2007, FDA determined that there is no barrier to patent delisting under this regulation. FDA Letter at 2. Similarly, FDA considered whether the exception to delisting recognized by the D.C. Circuit in Ranbaxy Labs. v. Leavitt, 469 F.2d 120, 126 (D.C. Cir. 2006, applied, and determined that it did not apply to these facts. 2 Section (c, 21 C.F.R., is the regulation that describes the operation of 180-day exclusivity. -7-
8 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 8 of 14 ARGUMENT I. THE COURT LACKS JURISDICTION TO REVIEW MYLAN S CLAIM OF CONTINUED ENTITLEMENT TO 180-DAY MARKETING EXCLUSIVITY Mylan admits that it is rearguing the 180-day exclusivity issue already decided by this Court, but claims that it is entitled to do so because the Court got it wrong. Mylan Br. at 2. Mylan, however, is not making this argument in the context of a motion for reconsideration. In fact, it moved for reconsideration and failed to raise this issue. Following reconsideration, it appealed this Court s decision to the D.C. Circuit. The filing of an appeal, even an interlocutory appeal such as in the instant case, deprives the Court of jurisdiction over issues involved in the appeal. The filing of a notice of appeal, including an interlocutory appeal, confers jurisdiction on the court of appeals and divests the district court of control over those aspects of the case involved in the appeal. The district court does not regain jurisdiction over those issues until the court of appeals issues its mandate. United States v. DeFries, 129 F.3d 1293, 1302 (D.C. Cir. 1997, quoting in part Griggs v. Provident Consumer Discount Co., 459 U.S. 56, 58 (1982. See also Fundicao Tupy S.A. v. United States, 841 F.2d 1101, (Fed. Cir (on appeal of a preliminary injunction, [t]he filing of a timely and sufficient notice of appeal has the effect of immediately transferring jurisdiction from the district court to the court of appeals with respect to any matters involved in the appeal. It divests the district court of authority to proceed further with respect to such matters.... (citation omitted; Decatur Liquors, Inc. v. District of Columbia, 384 F.Supp.2d 58, 60 n.1 (D.D.C ( On January 7, 2005, Defendants filed a motion to dissolve the preliminary injunction, which the Court denied because Defendants had appealed and the Court was without jurisdiction. See Decatur Liquors v. District of Columbia, 2005 WL , 2005 U.S. Dist. LEXIS 4246 (D.D.C. Mar. 16, Here, Mylan s appeal -8-
9 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 9 of 14 raises the very issue raised in its preliminary injunction motion whether it has a probability of success in showing that FDA s rejection of its request for 180 days of marketing exclusivity is arbitrary and capricious and this Court lacks jurisdiction over the instant motion. In addition, the law-of-the-case doctrine should prevent this Court from revisiting an issue it has already decided. [T]he same issue presented a second time in the same case in the same court should lead to the same result. LaShawn v. Barry, 87 F.3d 1389, 1393 (D.C. Cir (emphasis in original. See also Kimberlin v. Quinlan, 199 F.3d 496, 500 (D.C. Cir. 1999; Feirson v. District of Columbia, 362 F. Supp. 2d 244, 247 (D.D.C Mylan has not presented extraordinary circumstances that warrant reconsideration of this issue by the court. See LaShawn, 87 F.3d at II. FDA PROPERLY DETERMINED, AND THIS COURT PROPERLY HELD, THAT 180-DAY MARKETING EXCLUSIVITY EXPIRES WITH THE PATENT Even if the Court had jurisdiction to review its earlier determination and even if that holding were not the law of the case, the Court s finding that 180-day marketing exclusivity does not extend beyond patent exclusivity was clearly correct. As the Court recognized, the statutory mechanism for the application of 180-day exclusivity, by its terms, can only operate before the patent expires. Because an application containing the first paragraph IV certification blocks only other applications containing paragraph IV certifications, once the patent expires, and ANDAs no longer need to maintain their paragraph IV certifications, 180-day exclusivity is no longer a barrier to approval. Mylan argues that the rule should apply differently on these facts because its exclusivity vested before the patent expired. Mylan Br. at 8. However, the statute does not mention vesting, and Mylan cannot make a plain language argument in support of its vesting distinction. Instead, it argues that, under the plain language of the statute, there is no explicit -9-
10 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 10 of 14 provision that mandates that exclusivity terminate with patent expiration. See Mylan Br. at The Court has already rejected that argument; in its first motion emergency relief, Mylan argued that once triggered, the 180-day market exclusivity period remains regardless of the status of the patent. See 484 F. Supp. 2d at Mylan further asserts that policy arguments favor permitting it to maintain its exclusivity. Mylan Br. at However, the enactment of the Hatch-Waxman amendments involved the balancing of conflicting policy interests. See Tri-Bio Labs, Inc. v. United States, 836 F.2d 135, 139 (3d Cir. 1987, cert. denied, 488 U.S. 818 (1988. There is nothing sacrosanct about 180- day exclusivity that deserves protection above all other interests. Moreover, policy arguments cannot trump the clear statutory provisions. Mylan argues that FDA s interpretation produces absurd results. Mylan Br. at To reach this absurd result, it misrepresents FDA s analysis in the context of its pediatric exclusivity decision. Mylan Br. at 15. Mylan asserts that Apotex s ANDA still contains a paragraph IV certification and, by the express terms of the statute, cannot be approved during Mylan s 180-day generic exclusivity.... FDA s interpretation would lead to the absurd result that filers that certified under paragraph IV, and thus took on the risk of litigation (such as Apotex, were blocked by Mylan s 180-day exclusivity, while the FDA would be free to approve those who merely certified under paragraph II and III and took no risk at all. Mylan Br. at However, FDA did not conclude that Apotex maintained a paragraph IV certification. It found that all of the paragraph IV certifications, including Apotex s, converted to paragraph II 3 Mylan also attempts to distinguish the cases that have recognized that 180-day exclusivity expires with the patent on the ground that the cases did not involve a vested exclusivity. See Mylan Br. at This is a distinction without a difference: Mylan fails to explain anything in those decision that would support a different finding for vested exclusivity. -10-
11 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 11 of 14 certifications on patent expiration. FDA Letter at 9 ( When the 303 patent expired on March 25, 2007, all of the unapproved ANDAs were required to change (or deemed to have changed to paragraph II certifications and became subject to Pfizer s pediatric exclusivity at that time. That is their status during the period before the mandate issues. ; see also Government Appellees Corrected Opposition to Mylan s Motion for Injunction Pending Appeal, No at 14 (May 23, 2007 (After patent expiration, Apotex s ANDA was deemed to have a paragraph II certification and was subject to Pfizer s pediatric exclusivity. If the mandate did not issue before the pediatric exclusivity expired, or if the Federal Circuit reconsidered and reversed the panel decision, pediatric exclusivity would have continued to bar the approval of Apotex s ANDA until the pediatric exclusivity period expired.. Mylan s absurd results argument should be rejected because it is based on an erroneous premise. Accordingly, Mylan offers no compelling reason for the Court to question its previous holding on 180-day exclusivity. III. FDA PROPERLY DELISTED THE 303 PATENT Mylan has no basis to challenge the delisting of the patent. FDA s June 22, 2007, decision to remove the 303 patent from the Orange Book represents a clear application of the law. It is well established, and Mylan does not dispute, that FDA s role in listing patents is ministerial. See Apotex, Inc. v. Thompson, 347 F.3d 1335, (Fed. Cir. 2003; aaipharma, Inc. v. Thompson, 296 F.3d 227, 243 (4th Cir. 2002, cert. denied, 538 U.S. 923 (2003; Alphapharm Pty Ltd. v. Thompson, 330 F. Supp. 2d 1, 7-8 (D.D.C FDA generally defers to the NDA holder s assessment of whether a patent should be delisted, particularly when, as here, the NDA holder requests that the patent be removed from the Orange Book because it no -11-
12 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 12 of 14 longer meets the requirements for listing. Thus, the only question for the Court is whether there is an exception to delisting that requires that the patent stay in the Orange Book. The answer is no. FDA has established through regulation an exception to delisting when an ANDA applicant has filed a paragraph IV certification to that patent and is engaged in litigation related to that certification. However, the exception set forth in 21 C.F.R (a(12(viii by its very terms does not apply when the patent has expired. Mylan Ex. A at 2. Mylan relies heavily on Ranbaxy Labs. v. Leavitt, 469 F.2d 120, 126 (D.C. Cir. 2006, to argue that FDA may not delist patents when a paragraph IV certification has been filed. Ranbaxy, however, did not involve an expired patent and, in fact, the Court noted that the result would in all likelihood be different if the patent had expired. Id. at 126 n.*. In addition, the court cited and did not question the holding in Dr. Reddy Labs. v. Thompson, 302 F. Supp. 2d 340, (D.N.J. 2003, that 180-day exclusivity does not extend beyond patent expiration. See 469 F.2d at Further, because Pfizer sued Mylan on its paragraph IV certification, Ranbaxy Labs. is factually inapposite. To argue on these facts that the patent should not be removed from the Orange Book, Mylan resorts to urging the Court to apply 21 C.F.R (a(12(viii in part and strike it down in part. That is, Mylan seeks to have the Court require that FDA apply an exception to delisting to preserve Mylan s 180-day exclusivity claim, but, at the same time, strike down the language of the regulation that provides that the exception does not apply to expired patents. Mylan Br. at 8 ( The portion of the FDA s regulations... is arbitrary, capricious and contrary to law. ; see also Mylan Br. at And, to achieve this result, Mylan asks the Court to reverse its own holding that Mylan s entitlement to 180-day exclusivity terminated when the patent expired. The Court should not do so for two reasons. First, as discussed above, reconsideration -12-
13 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 13 of 14 of this Court s earlier decision is improper at this time. Second, this Court s holding on 180-day exclusivity was clearly correct, and Mylan has not offered any compelling reason to question it. Accordingly, once the patent was delisted, there can be no exclusivity on that patent and Mylan s application should be denied. IV. IRREPARABLE INJURY, THE BALANCE OF HARMS, AND THE PUBLIC INTEREST In its April 30 decision on Mylan s first motion for emergency relief, this Court rejected Mylan s claim that it would suffer irreparable injury absent a preliminary injunction. 484 F.Supp.2d at 123. Mylan makes no further showing in this second attempt at emergency relief that it will suffer a loss that would threaten the continued existence of [its] business. Id. In fact, inasmuch as Mylan already has competition from generic products (Apotex and Pfizer s generic, its claim is even weaker than it was previously. Additionally, this Court found that a faithful and coherent interpretation of the FDCA and Hatch-Waxman outweighs the purely financial harm to these drug companies. Id. at 124. The Court also held: The public interest does not favor a distortion of the principles of the Hatch-Waxman Act.... By ensuring that the FDA follows its mandate under Hatch-Waxman while at the same time ensuring that the FDA s management of ambiguities created by the statute and its regulations are reasonable, the court best protects the public s interest. Id. (citation omitted. Mylan has made no better showing in this round of briefing that the public interest or the balance of harms weigh in its favor. -13-
14 Case 1:07-cv RMU Document 81 Filed 06/27/2007 Page 14 of 14 be denied. CONCLUSION For the foregoing reasons, Mylan s application for a temporary restraining order should Of Counsel: DANIEL MERON General Counsel SHELDON T. BRADSHAW Associate General Counsel Food and Drug Division ERIC M. BLUMBERG Deputy Chief Counsel, Litigation Respectfully submitted, PETER D. KEISLER Assistant Attorney General C. FREDERICK BECKNER III Deputy Assistant Attorney General EUGENE M. THIROLF Director KAREN E. SCHIFTER Associate Chief Counsel, Litigation /s/ U.S. Dept. of Health & Human Services DRAKE CUTINI Office of the General Counsel Attorney 5600 Fishers Lane Office of Consumer Litigation Rockville, MD U.S. Department of Justice PO. Box 386 Washington, D.C Tel: Fax: drake.cutini@usdoj.gov -14-
Case 1:07-cv RMU Document 71-2 Filed 05/08/2007 Page 1 of 6. ANDA , Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg.
Case 1:07-cv-00579-RMU Document 71-2 Filed 05/08/2007 Page 1 of 6 DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 76-719, Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg. SENT BY FACSIMILE AND U.S. MAIL
More informationI'D [3, 2 7 ~ ~ a Anthony Figg Lisa N. Phillips
4 j ROTHWELL, FIGG, ERNST & MANBECK, P.c. 1425 K Street, N.W. G. Franklin Rothwell Anne M. Sterba Suite 800 6045 7 I'D [3, 2 7 ~ ~ a Anthony Figg Lisa N. Phillips Washington, D.C. 20005 : i-_. f~ ~azbara
More informationCase 1:14-cv IMK Document 125 Filed 06/16/14 Page 1 of 21 PageID #: 1959
Case 1:14-cv-00075-IMK Document 125 Filed 06/16/14 Page 1 of 21 PageID #: 1959 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA MYLAN PHARMACEUTICALS, INC., Plaintiff, WATSON
More informationSome Declaratory Judgment Guidance For ANDA Litigants
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Some Declaratory Judgment Guidance For ANDA Litigants
More informationCase 3:11-cv JAP -TJB Document 32 Filed 07/06/11 Page 1 of 19 PageID: 530 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 3:11-cv-03111-JAP -TJB Document 32 Filed 07/06/11 Page 1 of 19 PageID: 530 NOT FOR PUBLICATION UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY : NOSTRUM PHARMACEUTICALS, LLC, : : Plaintiff,
More informationFrom PLI s Program New Strategies Arising from the Hatch-Waxman Amendments #4888
From PLI s Program New Strategies Arising from the Hatch-Waxman Amendments #4888 New Strategies Arising From the Hatch-Waxman Amendments Practicing Law Institute Telephone Briefing May 12, 2004 I. INTRODUCTION
More informationCase: 1:16-cv Document #: 1 Filed: 03/09/16 Page 1 of 13 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION
Case: 1:16-cv-02988 Document #: 1 Filed: 03/09/16 Page 1 of 13 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION TORRENT PHARMACEUTICALS LIMITED, and TORRENT PHARMA
More informationIff/]) FEB Gregory 1. Glover Pharmaceutical Law Group PC 900 Seventh Street, NW Suite 650 Washington, DC
DEPARTMENT OF HEALTH &. HUMAN SERVICES FEB 2 2 2011 Food and Drug Administration Rockville MD 20857 Gregory 1. Glover Pharmaceutical Law Group PC 900 Seventh Street, NW Suite 650 Washington, DC 20001-3886
More informationRecent developments in US law: Remedies and damages for improper patent listings in the FDA s Orange Book
Daniel G. Brown is a partner in the New York law firm Frommer Lawrence & Haug, LLP, and practises extensively in the Hatch Waxman area. He has been practising in New York since 1993 in the patent and intellectual
More informationAttachment C M AY Daniel J. Tomasch, Esq. Orrick, Herrington & Sutcliffe LLP 666 Fifth Ave. New York, NY Dear Mr.
DEPARTMENT OF Hr.PILTH & HUMAN SERVICES Health Service Public Food and Drug Administration R ockviue MD 20857 Daniel J. Tomasch, Esq. Orrick, Herrington & Sutcliffe LLP 666 Fifth Ave. New York, NY 10103
More informationCase 3:14-cv MLC-TJB Document Filed 07/24/15 Page 2 of 16 PageID: 1111 TABLE OF CONTENTS INTRODUCTION... 1 BACKGROUND...
Case 3:14-cv-02550-MLC-TJB Document 100-1 Filed 07/24/15 Page 1 of 16 PageID: 1110 Keith J. Miller Michael J. Gesualdo ROBINSON MILLER LLC One Newark Center, 19th Floor Newark, New Jersey 07102 Telephone:
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 02-1295 APOTEX, INC., v. Plaintiff-Appellant, TOMMY G. THOMPSON, Secretary of Health and Human Services, U.S. FOOD AND DRUG ADMINISTRATION, and LESTER
More informationCase 1:14-cv IMK Document 103 Filed 05/29/14 Page 1 of 33 PageID #: 1860
Case 1:14-cv-00075-IMK Document 103 Filed 05/29/14 Page 1 of 33 PageID #: 1860 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA MYLAN PHARMACEUTICALS, INC., Plaintiff, WATSON
More informationORDER GRANTING IN PART AND DENYING IN PART MOTION TO TRANSFER OR STAY
Pfizer Inc. et al v. Sandoz Inc. Doc. 50 Civil Action No. 09-cv-02392-CMA-MJW IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Judge Christine M. Arguello PFIZER, INC., PFIZER PHARMACEUTICALS,
More informationAn ANDA Update. June 2004 Bulletin 04-50
June 2004 Bulletin 04-50 If you have questions or would like additional information on the material covered in this Bulletin, please contact one of the authors: Mark R. Shanks 202.414.9201 mshanks@reedsmith.com
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit TEVA PHARMACEUTICALS USA, INC., THROUGH ITS GATE PHARMACEUTICALS DIVISION, Plaintiff-Appellant, v. EISAI CO., LTD. AND EISAI MEDICAL RESEARCH, INC.,
More informationCase 8:14-cv GJH Document 14 Filed 08/19/14 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND
Case 8:14-cv-02662-GJH Document 14 Filed 08/19/14 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND HOSPIRA, INC., ) ) Plaintiff, ) ) v. ) CIVIL ACTION NO. ) 8:14-cv-02662-GJH
More informationCase 1:10-cv JCJ Document 20 Filed 04/14/10 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 110-cv-00137-JCJ Document 20 Filed 04/14/10 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MILLENNIUM PHARMACEUTICALS, INC. and SCHERING CORP., Plaintiffs, CIVIL ACTION
More information) ) Court to enter a preliminary injunction ordering the Food and Drug Administration ( FDA ) to
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ROXANE LABORATORIES, INC., ) ) ) Plaintiff, ) ) V. ) Civil Action No. - UNITED STATES FOOD AND DRUG ) ADMINISTRATION, et at,, ) )) ) Defendants.
More informationNo IN THE EISAI CO. LTD AND EISAI MEDICAL RESEARCH, INC., TEVA PHARMACEUTICALS USA, INC., through its GATE PHARMACEUTICALS Division,
No. 10-1070 ~[~ 2 7 7.i~[ IN THE EISAI CO. LTD AND EISAI MEDICAL RESEARCH, INC., Petitioners, TEVA PHARMACEUTICALS USA, INC., through its GATE PHARMACEUTICALS Division, Respondent. ON PETITION FOR A WRIT
More informationA. ANDAs and Eligibility for 180-day Exclusivity
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 SENT VIA ELECTRONIC MAIL Dear Celecoxib ANDA Applicant: This letter addresses the legal and regulatory scheme governing
More informationCaraco V. Novo Nordisk: Antitrust Implications
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Caraco V. Novo Nordisk: Antitrust Implications Law360,
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 2:06-cv-03462-WJM-MF Document 161 Filed 10/20/16 Page 1 of 7 PageID: 5250 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY DAIICHI SANKYO, LIMITED and DAIICHI SANKYO, INC., v. Plaintiffs
More informationHOGAN & HARTSON APR -9 P4 :18 BY HAND DELIVERY
HOGAN & HARTSON 2741 10 APR -9 P4 :18 Hogan & Hartson up Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 +1.202.637.5600 Tel +1.202.637.5910 Fax www.hhlaw.com Philip Katz Partner 202.637.5632
More informationCase: 1:10-cv Document #: 92 Filed: 12/06/10 Page 1 of 10 PageID #:1591
Case: 1:10-cv-05135 Document #: 92 Filed: 12/06/10 Page 1 of 10 PageID #:1591 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION RHONDA EZELL, JOSEPH I. BROWN, )
More informationON NOVEMBER 6, 2001, the U.S. Court of Appeals
21 Biotechnology Law Report 13 Number 1 (February 2002) Mary Ann Liebert, Inc. Brief Analysis of Recent Pharmaceutical/IP Decisions DAVID A. BALTO AMERICAN BIOSCIENCE, INC. V. THOMPSON 269 F.3D1077, 2001
More informationUnited States Court of Appeals for the Federal Circuit
Case: 14-1282 Case: CASE 14-1282 PARTICIPANTS Document: ONLY 44 Document: Page: 1 43 Filed: Page: 05/30/2014 1 Filed: 05/30/2014 2014-1282, -1291 United States Court of Appeals for the Federal Circuit
More informationPharmaceutical Patent Settlement Cases: Mixed Signals for Settling Patent Litigation
By Margaret J. Simpson Tel: 312 923-2857 Fax: 312 840-7257 E-mail: msimpson@jenner.com The following article originally appeared in the Spring 2004 issue of the Illinois State Bar Association s Antitrust
More informationFDA, PATENT TERM EXTENSIONS AND THE HATCH WAXMAN ACT. Dr.Sumesh Reddy- Dr. Reddys Lab Hyderabad-
FDA, PATENT TERM EXTENSIONS AND THE HATCH WAXMAN ACT Dr.Sumesh Reddy- Dr. Reddys Lab Hyderabad- FDA Regulatory approval-time and cost Focus of FDA approval process-safety and efficacy Difference between
More informationPHARMACEUTICAL LAW GROUP PC
in L PHARMACEUTICAL LAW GROUP PC AT THE INTERSECTION OF FDA REGULATION AND INTELLECTUAL PROPERTY 900 SEVENTH STREET, NW - SUITE 650 - WASHINGTON, DC 20001-3886 T 202 589 1780 F 202 318 2198 WWW.PHARMALAWGRP.COM
More informationIn the United States Court of Federal Claims
In the United States Court of Federal Claims No. 03-2371C (Filed November 3, 2003) * * * * * * * * * * * * * * * * * * * * * * * * * * * SPHERIX, INC., * * Plaintiff, * * Bid protest; Public v. * interest
More informationUnited States Court of Appeals for the Fourth Circuit
Appeal: 14-1522 Doc: 47 Filed: 08/01/2014 Pg: 1 of 74 Nos. 14-1522, 14-1529, 14-1593 United States Court of Appeals for the Fourth Circuit MYLAN PHARMACEUTICALS INC., WATSON LABORATORIES, INC., and LUPIN
More informationSupreme Court of the United States
NO. 15-307 In the Supreme Court of the United States MYLAN PHARMACEUTICALS INC., v. Petitioner, APOTEX INC., Respondent. On Petition for Writ of Certiorari to the U.S. Court of Appeals for the Federal
More informationCase 1:09-md SLR Document 273 Filed 05/20/11 Page 1 of 7 PageID #: 5592
Case 1:09-md-02118-SLR Document 273 Filed 05/20/11 Page 1 of 7 PageID #: 5592 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE: CYCLOBENZAPRINE ) HYDROCHLORIDE EXTENDED ) Civ. No.
More informationCase 1:12-cv SLR Document 18 Filed 08/27/12 Page 1 of 17 PageID #: 71 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:12-cv-00809-SLR Document 18 Filed 08/27/12 Page 1 of 17 PageID #: 71 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., WYETH LLC, WYETH PHARMACEUTICALS INC., and PF PRISM
More informationNo IN THE MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., & UDL LABORATORIES, INC.,
11 No. 08-1461 IN THE MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., & UDL LABORATORIES, INC., v. Petitioners, TAKEDA CHEMICAL INDUSTRIES, LTD. & TAKEDA PHARMACEUTICALS NORTH AMERICA, INC., Respondents.
More informationSUCCESSFULLY LITIGATING METHOD OF USE PATENTS IN THE U.S.
SUCCESSFULLY LITIGATING METHOD OF USE PATENTS IN THE U.S. The 10 th Annual Generics, Supergenerics, and Patent Strategies Conference London, England May 16, 2007 Provided by: Charles R. Wolfe, Jr. H. Keeto
More informationCase 2:09-cv DMC-MF Document 17 Filed 04/20/2009 Page 1 of 28 : :
Case 2:09-cv-01302-DMC-MF Document 17 Filed 04/20/2009 Page 1 of 28 WINSTON & STRAWN LLP The Legal Center One Riverfront Plaza, 7th Floor Newark, New Jersey 07102 (973) 848-7676 James S. Richter Attorneys
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 01-1369, -1370 MINNESOTA MINING AND MANUFACTURING COMPANY and RIKER LABORATORIES, INC., and ALPHAPHARM PTY. LTD., v. Plaintiffs-Appellants, Plaintiff-Appellant,
More informationCase 1:16-cv UNA Document 1 Filed 09/30/16 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00886-UNA Document 1 Filed 09/30/16 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC. and UCB PHARMA GMBH, v. Plaintiffs, AUROBINDO PHARMA
More informationPharmaceutical Formulations: Ready For Patenting?
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Pharmaceutical Formulations: Ready For Patenting?
More informationCase 1:12-cv RBW Document 9 Filed 12/03/12 Page 1 of 6 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:12-cv-01936-RBW Document 9 Filed 12/03/12 Page 1 of 6 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ENDO PHARMACEUTICALS INC., Plaintiff, v. Civil Action 12-1936 (RBW UNITED STATES FOOD
More informationCase 1:17-cv JDB Document 86 Filed 08/17/18 Page 1 of 9 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:17-cv-02325-JDB Document 86 Filed 08/17/18 Page 1 of 9 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE, et al., Plaintiffs, v.
More informationPharmaceutical Product Improvements and Life Cycle Management Antitrust Pitfalls 1
Pharmaceutical Product Improvements and Life Cycle Management Antitrust Pitfalls 1 The terms product switching, product hopping and line extension are often used to describe the strategy of protecting
More informationUNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY WARNER CHILCOTT COMPANY, LLC, et al., Plaintiffs, Civil Action No. 11-6936 (SRC) v. OPINION & ORDER TEVA PHARMACEUTICALS USA, INC., Defendant. CHESLER,
More informationCase 1:10-mc CKK -AK Document 31 Filed 07/13/10 Page 1 of 12 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:10-mc-00289-CKK -AK Document 31 Filed 07/13/10 Page 1 of 12 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA FEDERAL TRADE COMMISSION, Petitioner, v. PAUL M. BISARO, Misc. No. 10-289 (CKK)(AK)
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 2009-1071 ELI LILLY AND COMPANY, Plaintiff-Appellee, v. TEVA PHARMACEUTICALS USA, INC., Defendant-Appellant. Charles E. Lipsey, Finnegan, Henderson,
More informationIssue Brief for Congress Received through the CRS Web
Order Code IB10105 Issue Brief for Congress Received through the CRS Web The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents Updated November 25, 2002 Wendy H. Schacht and
More informationThe Korean Drug Approval-Patent Linkage System: A Comparison with the US Hatch-Waxman Act
FEBRUARY 2015 The Korean Drug Approval-Patent Linkage System: A Comparison with the US Hatch-Waxman Act Authors: Ki Young Kim, Hyunsuk Jin, Samuel SungMok Lee Pursuant to the implementation of the Korea-US
More informationPatent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues
Patent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues John R. Thomas Visiting Scholar February 9, 2012 CRS Report for Congress Prepared for Members and Committees of Congress
More informationUnited States Court of Appeals for the Federal Circuit
Case: 14-1282 Document: 62 Page: 1 Filed: 09/29/2014 2014-1282, -1291 United States Court of Appeals for the Federal Circuit APOTEX INC., Plaintiff-Appellant, v. DAIICHI SANKYO, INC., AND DAIICHI SANKYO
More informationCase 1:11-cv LPS Document 497 Filed 05/20/14 Page 1 of 9 PageID #: IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:11-cv-00704-LPS Document 497 Filed 05/20/14 Page 1 of 9 PageID #: 17900 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AVANIR PHARMACEUTICALS, INC., AVANIR HOLDING COMPANY, AND
More informationLupin Pharmaceutkals,Inc.
Lupin Pharmaceutkals,Inc. 1011 1 9 A 8 : 43 VIA FEDERAL EXPRESS Division of Documents Management Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane Room 1061 Rockville,
More informationPENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS
PENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS By Edward W. Correia* A number of bills have been introduced in the United States Congress this year that are intended to eliminate perceived
More informationPay-for-Delay Settlements: Antitrust Violation or Proper Exercise of Pharmaceutical Patent Rights?
Pay-for-Delay Settlements: Antitrust Violation or Proper Exercise of Pharmaceutical Patent Rights? By Kendyl Hanks, Sarah Jacobson, Kyle Musgrove, and Michael Shen In recent years, there has been a surge
More informationCase 1:05-cv JGP Document 79 Filed 03/05/2007 Page 1 of 7 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:05-cv-01181-JGP Document 79 Filed 03/05/2007 Page 1 of 7 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA MICHIGAN GAMBLING OPPOSITION ( MichGO, a Michigan non-profit corporation, Plaintiff,
More informationJurisdiction In Hatch-Waxman Actions Against Foreign Entities
Jurisdiction In Hatch-Waxman Actions Against Foreign Entities Law360, New York (October 19, 2015, 10:36 AM ET) - The 2014 U.S. Supreme Court decision in Daimler AG v. Bauman[1] has increased challenges
More informationCase 1:16-cv UNA Document 1 Filed 01/15/16 Page 1 of 13 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00015-UNA Document 1 Filed 01/15/16 Page 1 of 13 PageID #: 1 PROSTRAKAN, INC. and STRAKAN INTERNATIONAL S.á r.l., IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE v. Plaintiffs,
More informationCase 1:08-cv JDB Document 16 Filed 10/29/2009 Page 1 of 9 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:08-cv-01854-JDB Document 16 Filed 10/29/2009 Page 1 of 9 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA WILBUR WILKINSON, Plaintiff-Petitioner, v. Civil Action No. 08-1854 (JDB) 1 TOM
More informationCase 4:08-cv RP-RAW Document 34 Filed 01/26/2009 Page 1 of 6 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF IOWA CENTRAL DIVISION
Case 4:08-cv-00370-RP-RAW Document 34 Filed 01/26/2009 Page 1 of 6 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF IOWA CENTRAL DIVISION CARL OLSEN, ) ) Civil No. 4:08-cv-00370 (RWP/RAW) Plaintiff, )
More informationCase 1:11-cv RHS-WDS Document 5 Filed 11/10/11 Page 1 of 14 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO
Case 1:11-cv-00946-RHS-WDS Document 5 Filed 11/10/11 Page 1 of 14 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO LOS ALAMOS STUDY GROUP, v. Plaintiff, UNITED STATES DEPARTMENT OF ENERGY,
More informationA New History and Discussion of 180-Day Exclusivity
University of Missouri School of Law Scholarship Repository Faculty Publications 2009 A New History and Discussion of 180-Day Exclusivity Erika Lietzan University of Missouri School of Law, lietzane@missouri.edu
More informationCase 3:16-cv MAS-LHG Document 1 Filed 09/16/16 Page 1 of 14 PageID: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 3:16-cv-05678-MAS-LHG Document 1 Filed 09/16/16 Page 1 of 14 PageID: 1 Liza M. Walsh Tricia B. O Reilly Katelyn O Reilly WALSH PIZZI O REILLY FALANGA LLP 1037 Raymond Boulevard, Suite 600 Newark,
More informationo 1205 Culbreth Dr., Suite 200, Wilmington, NC Phone : Facsimile :
Osmotica Pharmaceutical 1?54,Lt. 27 P2 :05 BY HAND DELIVERY Division of Dockets Management Food and Drug Administration Department of Health and Human Services 563"0 Fishers Lane, Room 1061 Rockville,
More informationDIRECT PURCHASERS STANDING TO SUE FOR WALKER PROCESS FRAUD IN RE: DDAVP DIRECT PURCHASER ANTITRUST LITIGATION
DIRECT PURCHASERS STANDING TO SUE FOR WALKER PROCESS FRAUD IN RE: DDAVP DIRECT PURCHASER ANTITRUST LITIGATION Rick Duncan Denise Kettleberger Melina Williams Faegre & Benson, LLP Minneapolis, Minnesota
More information5 Red Flags In Pharmaceutical Settlements
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com 5 Red Flags In Pharmaceutical Settlements Law360,
More informationCase: 5:16-cv JRA Doc #: 8 Filed: 11/30/16 1 of 8. PageID #: 111 IN THE UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION
Case: 5:16-cv-02889-JRA Doc #: 8 Filed: 11/30/16 1 of 8. PageID #: 111 IN THE UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION MICHAEL PENNEL, JR.,, vs. Plaintiff/Movant, NATIONAL
More informationCase 3:12-cv PGS-LHG Document 1 Filed 06/25/12 Page 1 of 41 PageID: 1
Case 3:12-cv-03893-PGS-LHG Document 1 Filed 06/25/12 Page 1 of 41 PageID: 1 Liza M. Walsh CONNELL FOLEY LLP 85 Livingston Avenue Roseland, New Jersey 07068 (973) 535-0500 Of Counsel: Dimitrios T. Drivas
More informationCase 1:11-cv RLV Document 103 Filed 08/23/12 Page 1 of 7 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF GEORGIA ATLANTA DIVISION.
Case 1:11-cv-01634-RLV Document 103 Filed 08/23/12 Page 1 of 7 INTENDIS, INC. and DOW PHARMACEUTICAL SCIENCES, INC., Plaintiffs, UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF GEORGIA ATLANTA DIVISION
More informationNo FOREST LABORATORIES, INC., FORES~LASO~TO~S Hot~mes, L~., ~D H. LU~.CK A/S, Petitioners,
No. 08-624 FOREST LABORATORIES, INC., FORES~LASO~TO~S Hot~mes, L~., ~D H. LU~.CK A/S, Petitioners, CARACO PHARI~CEUTICAL LABORATORIES, L~D., Respondent. On Petition for Writ of Certiorari To the United
More informationMEMORANDUM OPINION AND ORDER. arbitrable. Concluding that the arbitrator, not the court, should decide this issue, the court
Case 3:16-cv-00264-D Document 41 Filed 06/27/16 Page 1 of 14 PageID 623 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION A & C DISCOUNT PHARMACY, L.L.C. d/b/a MEDCORE
More informationCase 5:17-cv KS-MTP Document 51 Filed 10/19/17 Page 1 of 7
Case 5:17-cv-00088-KS-MTP Document 51 Filed 10/19/17 Page 1 of 7 IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF MISSISSIPPI WESTERN DIVISION RICHLAND EQUIPMENT COMPANY, INC. PLAINTIFF
More informationHealth Care Law Monthly
Health Care Law Monthly February 2013 Volume 2013 * Issue No. 2 Contents: Copyright ß 2013 Matthew Bender & Company, Inc., a member of the Lexis- Nexis group of companies. All rights reserved. HEALTH CARE
More information(4- I. Background. Douald O. Beers Arnold & Porter LLP 555 Twelfth Street, N.W. Washington, D.c
(4- DEPARTMENT OF HEALTH &. HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 Douald O. Beers Arnold & Porter LLP 555 Twelfth Street, N.W. Washington, D.c. 20004-1206
More informationCase 2:06-cv WJM-MF Document 157 Filed 10/07/16 Page 1 of 35 PageID: 4865 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 2:06-cv-03462-WJM-MF Document 157 Filed 10/07/16 Page 1 of 35 PageID: 4865 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY DAIICHI SANKYO COMPANY, LIMITED and DAIICHI SANKYO, INC., v.
More informationCase 1:18-cv RC Document 23 Filed 12/03/18 Page 1 of 5 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:18-cv-02084-RC Document 23 Filed 12/03/18 Page 1 of 5 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA THE AMERICAN HOSPITAL ASSOCIATION, et al., Plaintiffs, v Civil Action No. 18-2084
More informationIN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA ALEXANDRIA DIVISION
IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA ALEXANDRIA DIVISION MALIK JARNO, Plaintiff, v. ) ) Case No. 1:04cv929 (GBL) DEPARTMENT OF HOMELAND SECURITY, Defendant. ORDER THIS
More informationUNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION
Chapman et al v. J.P. Morgan Chase Bank, N.A. et al Doc. 37 UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION BILL M. CHAPMAN, JR. and ) LISA B. CHAPMAN, ) ) Plaintiffs, ) )
More informationSupreme Court of the United States
No. 15-1055 IN THE Supreme Court of the United States SMITHKLINE BEECHAM CORPORATION, D/B/A GLAXOSMITHKLINE; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS, USA, Petitioners, v. KING DRUG COMPANY
More informationUNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT. No WATSON LABORATORIES, INCORPORATED; LUPIN PHARMACEUTICALS, INCORPORATED,
Ý» ïæïìó½ªóðððéëó ÓÕ Ü±½«³»² ïíê Ú»¼ ïîñïêñïì Ð ¹» ï ±º ïé Ð ¹» Ü ýæ îððí Appeal: 14-1522 Doc: 61 Filed: 12/16/2014 Pg: 1 of 17 UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 14-1522
More informationAttorneys for Defendants Watson Laboratories, Inc. and Watson Pharmaceuticals, Inc.
Case 2:10-cv-00080-FSH -PS Document 15 Filed 03/01/10 Page 1 of 14 HELLRING LINDEMAN GOLDSTEIN & SIEGAL LLP Matthew E. Moloshok, Esq. Robert S. Raymar, Esq. One Gateway Center Newark, New Jersey 07102-5386
More informationCase 3:17-cv WHO Document 108 Filed 05/22/17 Page 1 of 8
Case :-cv-00-who Document 0 Filed 0// Page of 0 0 CHAD A. READLER Acting Assistant Attorney General BRIAN STRETCH United States Attorney JOHN R. TYLER Assistant Director STEPHEN J. BUCKINGHAM (Md. Bar)
More informationCase 1:16-cv JPO Document 75 Filed 09/16/16 Page 1 of 11 X : : : : : : : : : : : : : : : : : : : X. Plaintiffs,
Case 116-cv-03852-JPO Document 75 Filed 09/16/16 Page 1 of 11 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ------------------------------------------------------------- COMCAST CORPORATION,
More informationUnited States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT
USCA Case #18-5257 Document #1766994 Filed: 01/04/2019 Page 1 of 5 United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT No. 18-5257 September Term, 2018 FILED ON: JANUARY 4, 2019 JANE DOE
More informationBNA s Patent, Trademark & Copyright Journal
BNA s Patent, Trademark & Copyright Journal Reproduced with permission from BNA s Patent, Trademark & Copyright Journal, 91 PTCJ 1505, 3/25/16. Copyright 2016 by The Bureau of National Affairs, Inc. (800-372-1033)
More information"'031 Patent"), and alleging claims of copyright infringement. (Compl. at 5).^ Plaintiff filed its
Case 1:17-cv-03653-FB-CLP Document 83 Filed 09/12/18 Page 1 of 10 PageID #: 1617 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK POPSOCKETS LLC, -X -against- Plaintiff, QUEST USA CORP. and ISAAC
More informationUNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY. This Court dismissed the complaint of Direct Purchaser Plaintiffs Louisiana Wholesale
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY IN RE LAMICTAL DIRECT PURCHASER ANTITRUST LITIGATION THIS DOCUMENT RELATES TO: ALL DIRECT PURCHASER ACTIONS : : : : OPINION : : No. 12-cv-995 (WHW) :
More informationLitigation Webinar Series. Hatch-Waxman 101. Chad Shear Principal, San Diego
Litigation Webinar Series Hatch-Waxman 101 Chad Shear Principal, San Diego 1 Overview Hatch-Waxman Series Housekeeping CLE Contact: Jane Lundberg lundberg@fr.com Questions January 25, 2018 INSIGHTS Litigation
More informationCase 1:10-cv MGC Document 11-1 Filed 11/18/10 Page 1 of 55 EXHIBIT A
Case 1:10-cv-08386-MGC Document 11-1 Filed 11/18/10 Page 1 of 55 EXHIBIT A Case 1:10-cv-08386-MGC Document 11-1 Filed 11/18/10 Page 2 of 55 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW
More informationUNITED STATES COURT OF APPEALS TENTH CIRCUIT ORDER AND JUDGMENT * Before BRISCOE, Chief Judge, LUCERO and McHUGH, Circuit Judges.
FILED United States Court of Appeals Tenth Circuit October 23, 2014 UNITED STATES COURT OF APPEALS Elisabeth A. Shumaker Clerk of Court TENTH CIRCUIT PARKER LIVESTOCK, LLC, Plaintiff - Appellant, v. OKLAHOMA
More informationCase 1:18-cv LY Document 32-2 Filed 06/25/18 Page 1 of 8 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION
Case 1:18-cv-00295-LY Document 32-2 Filed 06/25/18 Page 1 of 8 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION COMMUNITY FINANCIAL SERVICES ASSOCIATION OF AMERICA, LTD., and CONSUMER
More informationCase 3:14-cv MLC-TJB Document 108 Filed 08/25/15 Page 1 of 19 PageID: 1168 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 3:14-cv-02550-MLC-TJB Document 108 Filed 08/25/15 Page 1 of 19 PageID: 1168 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY AMARIN PHARMA, INC. and AMARIN PHARMACEUTICALS IRELAND
More informationCase 8:14-cv GJH Document 1 Filed 08/19/14 Page 1 of 22
Case 8:14-cv-02662-GJH Document 1 Filed 08/19/14 Page 1 of 22 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND Hospira, Inc. 275 N. Field Drive Lake Forest, IL 60045, v. Plaintiff, Sylvia
More informationA. Bayer's New Drug Application for Precose
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 William A. Rakoczy, Esq. Rakoczy, Molino, Mazzochi & Siwik, LLP 6 West Hubbard St. Suite 500 Chicago, IL 60610 Dear
More informationWe have carefully considered the Petition.! For the reasons described below, the Petition is granted.
DEPARTMENT OF HEALTH &. HUMAN SERVICES... -------------_._- Food and Drug Administration Rockville MD 20857 JUN 17 2010. Pankaj Dave, Ph.D. Vice President, Regulatory Affairs Navinta LLC 1499 Lower Ferry
More informationSupreme Court of the United States
No. 10-844 IN THE Supreme Court of the United States CARACO PHARMACEUTICAL LABORATORIES, LTD., et al., Petitioners, v. NOVO NORDISK A/S, et al., Respondents. On Writ of Certiorari to the United States
More informationUNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION
UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION BARBARA GRUTTER, vs. Plaintiff, LEE BOLLINGER, et al., Civil Action No. 97-CV-75928-DT HON. BERNARD A. FRIEDMAN Defendants. and
More informationCase 1:17-cv UNA Document 1 Filed 12/22/17 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:17-cv-01844-UNA Document 1 Filed 12/22/17 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AMGEN INC., v. Plaintiff, TORRENT PHARMACEUTICALS LTD. and TORRENT
More informationCase 1:07-cv PLF Document 212 Filed 03/31/17 Page 1 of 13 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:07-cv-01144-PLF Document 212 Filed 03/31/17 Page 1 of 13 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA UNITED STATES OF AMERICA, ex rel., AARON J. WESTRICK, Ph.D., Civil Action No. 04-0280
More informationCase 3:15-cv MAS-LHG Document 1 Filed 04/06/15 Page 1 of 38 PageID: 1
Case 3:15-cv-02520-MAS-LHG Document 1 Filed 04/06/15 Page 1 of 38 PageID: 1 Liza M. Walsh, Esq. CONNELL FOLEY LLP 85 Livingston Avenue Roseland, New Jersey 07068-1765 (973) 535-0500 Of Counsel: William
More information